Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Submitted by
admin
on March 27, 2017 - 9:52am
Source:
Marketwatch
News Tags:
Vivus
Stendra
Sanofi
erectile dysfunction
Headline:
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Do Not Allow Advertisers to Use My Personal information
